ArticleOncology letters2026
Deep learning model based on CT images to predict Ki-67 expression in renal carcinoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to establish a preoperative prediction model of Ki-67 expression in renal cell carcinoma (RCC) by combining CT images of RCC with deep learning technology, and to evaluate its effect in clinical application. A retrospective analysis was performed on the CT images and pathological data of 137 patients with RCC who underwent renal CT plain scan plus enhancement scans and who were diagnosed pathologically from January 2019 to November 2023 at the Affiliated Hospital of Hebei University. All recruited patients were divided into 35 cases with Ki-67 ≥10% and 102 cases with Ki-67 <10% based on Ki-67 expression. Of these, 110 patients were divided into the training group and the test group in a 4:1 ratio, and the remaining 27 cases were used as a clinical validation group. Using the Mobilenetv3-large model, prediction models incorporating plain scan, arterial, venous and excretion phases were constructed using the training set data. The predictive performance of the models, including accuracy, accuracy, sensitivity, specificity, F1 score and area under the curve (AUC) values, were assessed by inputting CT images of the test group. The best-performing model was applied to the clinical validation group to compare the predicted results with the actual results of pathology; the accuracy, sensitivity, specificity and k coefficient of the model were calculated to assess its clinical efficacy. The Mobilenetv3-large model in the venous phase showed the best performance in terms of accuracy, sensitivity and F1 score, as well as relatively high precision and AUC value, indicating good robustness. In the clinical validation group, the model predicted Ki-67 expression with an accuracy of 0.814, sensitivity and specificity of 0.889 and 0.667 at low and high levels, respectively, and a k coefficient of 0.57. The Mobilenetv3-large model, when applied to venous-phase CT images, demonstrates notable clinical utility. It can proficiently forecast Ki-67 expression levels, thereby offering a precise, expedient and non-invasive aid in the formulation of tailored therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.